APGE
insider transactionsApogee Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-25.5K
0 buy · 25.5K sell
Net value · 30d
-$2.1M
$0 in · $2.1M out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
7
0 buy · 25.5K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Executive Officer · 10b5-1
$53.4K
614 sh · $86.89
Own -0%
-
Sell·S
Chief Executive Officer · 10b5-1
$198.9K
2.3K sh · $86.27
Own -0%
-
Sell·S
Chief Executive Officer · 10b5-1
$134.3K
1.6K sh · $85.19
Own -0%
-
Sell·S
Chief Executive Officer · 10b5-1
$90.9K
1.1K sh · $84.18
Own -0%
-
Sell·S
Chief Executive Officer · 10b5-1
$633.6K
7.7K sh · $82.78
Own -1%
-
Sell·S
Chief Executive Officer · 10b5-1
$556.6K
6.8K sh · $82.21
Own -1%
-
Grant·A
$0
7.7K sh
Own New
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
7.7K sh
Own New
-
Grant·A
Director
$0
7.7K sh
Own New
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
4.1K sh
Own +4%
-
Sell·S
Chief Medical Officer · 10b5-1
$432.9K
5.5K sh · $78.71
Own -3%
-
Exercise·M
Chief Medical Officer · 10b5-1
$94.3K
4.1K sh · $22.86
Own +2%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 10, 2026 | Michael Thomas Henderson KEY 10b5-1 | Sell S | 614 | $53.4K |
| Jun 10, 2026 | Michael Thomas Henderson KEY 10b5-1 | Sell S | 2.3K | $198.9K |
| Jun 10, 2026 | Michael Thomas Henderson KEY 10b5-1 | Sell S | 1.6K | $134.3K |
| Jun 10, 2026 | Michael Thomas Henderson KEY 10b5-1 | Sell S | 1.1K | $90.9K |
| Jun 10, 2026 | Michael Thomas Henderson KEY 10b5-1 | Sell S | 7.7K | $633.6K |
| Jun 10, 2026 | Michael Thomas Henderson KEY 10b5-1 | Sell S | 6.8K | $556.6K |
| Jun 9, 2026 | Fairmount Funds Management LLC / Tomas Kiselak | Grant A | 7.7K | $0 |
| Jun 9, 2026 | Nimish P Shah | Grant A | 7.7K | $0 |
| Jun 9, 2026 | Mark C. Mckenna | Grant A | 7.7K | $0 |
| Jun 9, 2026 | William A Jones JR | Grant A | 7.7K | $0 |
| Jun 9, 2026 | Jennifer A. Fox | Grant A | 7.7K | $0 |
| Jun 9, 2026 | Lisa Bollinger | Grant A | 7.7K | $0 |
| Jun 3, 2026 | Carl Dambkowski 10b5-1 | Exercise M | 4.1K | $0 |
| Jun 3, 2026 | Carl Dambkowski 10b5-1 | Sell S | 5.5K | $432.9K |
| Jun 3, 2026 | Carl Dambkowski 10b5-1 | Exercise M | 4.1K | $94.3K |
About APGE insider trading
This page tracks insider transactions for Apogee Therapeutics, Inc. (APGE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.